Skip to content

Hemolytic Uremic Syndrome Atypical Susceptibility To 7 C3808620

Published: July 22, 2026Updated: August 20, 2026

A genetic predisposition to atypical hemolytic uremic syndrome, a condition causing kidney damage from abnormal blood cell breakdown. It can affect both children and adults. Ongoing medical care is essential to manage episodes.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q63.9
ICD-11
LA00.0
Body system
renal
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Low urine output

!

Hypertension

Changes in urination or swelling

(renal)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Pallor

(renal)

Bleeding tendency

(renal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Renal disease management

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Terminal Complement Inhibition

C5 inhibitor therapy represents the standard of care for atypical HUS, blocking the terminal complement pathway to prevent ongoing microvascular thrombosis and hemolysis.

medication
3

Therapeutic Plasma Exchange

Extracorporeal removal of plasma containing complement-activating immune complexes with simultaneous replacement using fresh frozen plasma or albumin solution.

procedure

Additional treatment options

Hematologic Laboratory Surveillance

Frequent monitoring of complete blood count, LDH, haptoglobin, bilirubin, and schistocytes on peripheral smear to assess disease activity and treatment response.

monitoring

Antihypertensive Management

Blood pressure control using appropriate agents to protect renal and cardiovascular systems, as hypertension commonly accompanies atypical HUS.

medication

Infection Prevention Measures

Strict hygiene practices and prophylactic measures to prevent infections, which can trigger atypical HUS flares. Includes vaccination when appropriate.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Hemolytic Uremic Syndrome Atypical Susceptibility To 7 C3808620?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Hemolytic Uremic Syndrome Atypical Susceptibility To 7 C3808620. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy